Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Enrollment under way in ORIGIN trial

Feb. 20, 2004

Arexis acquires BSSL project from AstraZeneca

Feb. 20, 2004

Dow to produce NLC-001 in plant-based system

Feb. 19, 2004

Roche presents novel NPY antagonists with potential in obesity and other disorders

Feb. 19, 2004

Novel PPARdelta agonists under study at Bayer

Feb. 19, 2004

Two series of MCH1 antagonists and their use reported by Synaptic researchers

Feb. 19, 2004

New orexin antagonists for obesity and sleep disorders in early development at Actelion

Feb. 18, 2004

AstraZeneca claims MCH-1R antagonists with potential as antiobesity agents

Feb. 18, 2004

Improved postprandial glycemia found with HIM2 in type 1 diabetes

Feb. 18, 2004

Dermatrends demonstrates effective transdermal delivery of testosterone

Feb. 17, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 29, 2026.
ENCALS 2026: From genetics to advancing strategies against ALS
BioWorld Science
Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
Next wave of BCI firms builds on pioneers to tackle challenges
BioWorld
With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
Elixirgen and Nippon Shinyaku sign EXG-7001 option agreement
BioWorld Science
Elixirgen Therapeutics Inc. has entered into an option agreement with Nippon Shinyaku Co. Ltd. for the development and commercialization of EXG-7001 for Duchenne...
Investors bet on transformative BCI tech for neuro disorders
BioWorld
An estimated $2 billion has been invested in the brain-computer interface (BCI) space in the last two years and the level of funding is expected to continue....